Last reviewed · How we verify
IV Abatacept
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.
At a glance
| Generic name | IV Abatacept |
|---|---|
| Also known as | Switch from SC to IV Abatacept and back |
| Sponsor | Rüdiger B. Müller |
| Drug class | T-cell costimulation inhibitor |
| Target | CD80/CD86 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Abatacept (CTLA4-Ig) acts as a selective costimulation modulator that interrupts the second signal required for full T-cell activation. By binding to CD80 and CD86 molecules on antigen-presenting cells, it prevents interaction with CD28 on T cells, effectively suppressing the adaptive immune response. This mechanism makes it particularly useful in autoimmune conditions where T-cell-mediated inflammation drives disease pathology.
Approved indications
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Systemic lupus erythematosus
Common side effects
- Infection (upper respiratory, urinary tract)
- Headache
- Nausea
- Dizziness
- Hypertension
- Serious infections
Key clinical trials
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (PHASE1)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Carfilzomib and Belatacept for Desensitization (PHASE1, PHASE2)
- Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes (PHASE2)
- Tolerance by Engaging Antigen During Cellular Homeostasis (PHASE1)
- Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
- Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Abatacept CI brief — competitive landscape report
- IV Abatacept updates RSS · CI watch RSS
- Rüdiger B. Müller portfolio CI